At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
QM1114-DPbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label Study to Assess Aesthetic Improvement Following Treatment With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating QM1114-DP for Glabellar Frown Lines and Canthal Lines. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This study to assess aesthetic improvement following treatment with QM1114-DP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines, Canthal Lines
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartJan 2023
Primary CompletionMar 2023
Study CompletionJun 2023
TodayJul 2026
First PostedDec 7, 2021
Enrollment StartJan 23, 2023
Primary CompletionMar 31, 2023
Study CompletionJun 23, 2023
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.6 years ago
Interventions
QM1114-DPbiological
QM1114-DP